BMS reports mixed results for Opdivo in lung cancer trial - Drug Development Technology

BMS reports mixed results for Opdivo in lung cancer trial  Drug Development Technology

BMS has reported mixed results from the Phase III CheckMate -227 trial of Opdivo in combination with chemotherapy or its other drug Yervoy.



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development